View Older Stories View More Recent Stories
-
Summit Therapeutics (SMMT): Ivonescimab Plus Chemo Demonstrates Statistically Significant and Clinically Meaningful Improvement in PFS in Patients with EGFR-Mutant NSCLC
-
Citizens JMP: Standard of Care Modifying Regimens at ASCO 2025
-
Citizens JMP shares updates on cancer treatment stocks
-
Clear Street Starts Summit Therapeutics plc (SMMT) at Buy
-
TD Cowen Upgrades Summit Therapeutics plc (SMMT) to Buy
-
Cantor Fitzgerald Reiterates Overweight Rating on Summit Therapeutics plc (SMMT)
-
Summit Therapeutics (SMMT) Tops Q1 EPS by 2c
-
H.C. Wainwright Reiterates Buy Rating on Summit Therapeutics plc (SMMT)
-
Summit Therapeutics (SMMT) options active on volume of 49K contracts
-
Citizens JMP Reiterates Market Outperform Rating on Summit Therapeutics plc (SMMT)
-
Summit Therapeutics (SMMT) to Resume Trading at 3:30 p.m.
-
Summit Therapeutics (SMMT): Interim OS Analysis Requested from Chinese Health Authorities Shows Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive A
-
Summit Therapeutics (SMMT) Halted, News Pending
-
Summit Therapeutics (SMMT) Halted on Volatility, Down 34%
-
BioNTech SE (BNTX) Hits Low, Down 8%, Summit Therapeutics (SMMT) Falls 18.5%
-
Increasing unusual put option volume: AZUL BYND SMMT TMC VERU TMUS CHTR SPHR
-
H.C. Wainwright Reiterates Buy Rating on Summit Therapeutics plc (SMMT)
-
Cantor Fitzgerald Reiterates Overweight Rating on Summit Therapeutics plc (SMMT)
-
Citizens JMP Reiterates Market Outperform Rating on Summit Therapeutics plc (SMMT)
-
Truist Securities Reiterates Buy Rating on Summit Therapeutics plc (SMMT)
-
Truist Securities Reiterates Buy Rating on Summit Therapeutics plc (SMMT)
-
Cantor Fitzgerald Reiterates Overweight Rating on Summit Therapeutics plc (SMMT)
-
Cantor Fitzgerald Reiterates Overweight Rating on Summit Therapeutics plc (SMMT)
-
Citi Upgrades Summit Therapeutics plc (SMMT) to Buy
-
Summit Therapeutics (SMMT) grants inducement awards
-
Cantor Fitzgerald Starts Summit Therapeutics plc (SMMT) at Overweight
-
Summit Therapeutics (SMMT) appoints Robert LaCaze as CCO
-
Summit Therapeutics (SMMT) reports inducement grants
-
Evercore ISI Starts Summit Therapeutics plc (SMMT) at Outperform
-
Stifel Reiterates Buy Rating on Summit Therapeutics plc (SMMT)
-
H.C. Wainwright Reiterates Buy Rating on Summit Therapeutics plc (SMMT)
-
Stifel Reiterates Hold Rating on Summit Therapeutics plc (SMMT)
-
Summit Therapeutics (SMMT) Announces Clinical Trial Collaboration with Pfizer (PFE) to Evaluate Ivonescimab in Combination with Pfizer Antibody Drug Conjugates (ADCs)
-
Summit Therapeutics (SMMT) Tops Q4 EPS by 1c
-
H.C. Wainwright Reiterates Buy Rating on Summit Therapeutics plc (SMMT)
-
Truist Securities Starts Summit Therapeutics plc (SMMT) at Buy
-
Jefferies Starts Summit Therapeutics plc (SMMT) at Buy
-
H.C. Wainwright Reiterates Buy Rating on Summit Therapeutics plc (SMMT)
-
JMP Securities Starts Summit Therapeutics plc (SMMT) at Market Outperform
-
Summit Therapeutics plc (SMMT) PT Lowered to $44 at H.C. Wainwright
-
Summit Therapeutics (SMMT) Tops Q3 EPS by 2c
-
Summit Therapeutics (SMMT): FDA granted Fast Track designation for proposed use of ivonescimab in combination with platinum-based chemotherapy for the treatment of EGFRm NSCLC
-
H.C. Wainwright Reiterates Buy Rating on Summit Therapeutics plc (SMMT)
-
Increasing unusual put option volume: ASHR PPL MT SATS SAVA GEHC IONQ SMMT
-
Citi Downgrades Summit Therapeutics plc (SMMT) to Neutral, 'Valuation Looking Fair for Now'
-
Citi Downgrades Summit Therapeutics plc (SMMT) to Neutral, 'Valuation Looking Fair for Now'
-
Summit Therapeutics plc (SMMT) PT Raised to $40 at Stifel
-
Increasing unusual call option volume: CYH XND LUNR TRU EXC SMMT FWRD FDX GRAB CEG
-
Increasing unusual option volume: CNM MULN SMAR COMP IMAX SMMT TRU AZUL XLI EMB CARR
-
Summit Therapeutics plc (SMMT) PT Raised to $45 at H.C. Wainwright

